Gunaratne GS , Johns ME , Hintz HM , Walseth TF , Marchant JS .

R01 GM088790 NIGMS NIH HHS

	Fig. 1. Drugs that inhibit NAADP-evoked Ca2+ release block MERS translocation. A, Ca2+ release in sea urchin egg homogenate as resolved by fluo-3 fluorescence measurements. Ca2+ liberation was measured in the absence (solid circles, top trace) or presence of fangchinoline (open circles, 10μM) in response to NAADP (blue, 70 nM), IP3 (red, 200 nM) or cADPR (green, 100 nM). Data represent values from a minimum of three independent experiments and are expressed as mean ± SEM. B, correlation plot comparing the extent of inhibition of NAADP- (blue) IP3- (red) or cADPR-evoked Ca2+ release (green) observed with individual ligands (10μM) correlated with the extent of inhibition of MERS-pseudovirus translocation evoked by the same ligands (at the same concentration, 10μM). None of these tested ligands evoked Ca2+ release by themselves. Solid (NAADP) and dotted lines (IP3, cADPR) represent linear regression of datapoints. Ligand key: 1 = DMSO, 2=Cycleanine, 3=Tubocurarine, 4=Nimodipine, 5=Procaine, 6=Chondocurine, 7=Benzocaine, 8=Hernandezine, 9=Berbamine, 10=Nicardipine, 11=Verapamil, 12=Tetrandrine, 13=Fangchinoline, 14=Amitriptyline, 15=Loperamide, 16=Ned-19, 17=Bafilomycin, 18=U18666 A, 19 = YM201636, 20=Fluoxetine, 21=Citalopram, 22=Desipramine, 23=Siramesine. MERS-pseudovirus infectivity was measured using a luciferase-based cell entry assay, assay methodology and inhibition of NAADP-evoked Ca2+ shown in this figure are described in detail in the companion paper [25].
	Fig. 2. Schematic of workflow for identification of inhibitors of NAADP-evoked Ca2+ release and screening assay validation. A, Illustration of screening workflow. Small molecule libraries (1534 compounds) were screened for inhibitors of NAADP-evoked Ca2+ release in sea urchin egg homogenate. Primary screen hits were validated and characterized prior to testing against Ca2+ signals evoked by NAADP microinjection and pseudotyped MERS-CoV cell entry in mammalian cells. B, Representative traces of fluo-3 fluorescence for negative control in response to addition of vehicle (1st injection) and then NAADP (2nd injection, 167 nM) at indicated timepoints (arrows). C, Representative traces showing example of positive control (initial injection with NAADP, 167 nM). D, Representative traces of fluo-3 fluorescence used to measure Z’ after the 2nd injection timepoint (arrows).
	Fig. 3. Identification of top hits from primary drug screen. A, Scatter plot of average peak amplitude of NAADP-evoked Ca2+ release in the presence of drug (25μM) from LOPAC®1280 (left, numbered 1–1280) or Selleck (GPCR) compound library (right, numbered 1281–1534). B, results from both libraries were combined and compounds were ranked by amplitude of response from greatest inhibition (rank #1, left) to potentiation (rank #1534, right). The majority of compounds were in a range ±25% of control response (shaded box). Compounds that exhibited >80% inhibition of NAADP-evoked Ca2+ release were prioritized (red box) and selected for further characterization (Table 1). C, raw data from the primary screen for selected compounds – PPADS, PPNDS, thapsigargin, A23187, thio-NADP and vehicle control (DMSO). D, enlargement of red box from ‘B’ showing ranking of top eighteen hits after pruning, which displayed >80% inhibition of NAADP-evoked Ca2+ release. Pruned compounds were thio-NADP and A23187 (4th and 5th top hits), shown in grey. E, traces of NAADP-evoked Ca2+ release in the presence of the two top ranked candidates (#1, PF-543; #2, SKF96365; coloured lines, 25μM).
	Fig. 4. Secondary validation of candidates in sea urchin egg homogenate. A, Full concentration response curves resolving effects of selected primary screen candidates on Ca2+ release in sea urchin egg homogenates evoked by NAADP (70 nM). Current NAADP antagonists (PPADS, ned-19 and naringenin) are also included. IC50 values for the entire dataset are provided in Table 1. B, Averaged peak Ca2+ release in the presence of drug (30μM, 5 min preincubation time) relative to vehicle controls, in response to EC70 concentrations of NAADP (70 nM), cADPR (100 nM), or IP3 (200 nM). C, Analysis of effects of all 18 candidates on specific 32P-NAADP radioligand binding levels in the presence of drug (30μM), relative to vehicle controls. p-values: ** p < 0.01 relative to DMSO controls.
	Fig. 5. Characterization of candidate inhibitors on lysosomal Ca2+ stores in U2OS cells. A, representative traces of GPN induced Ca2+ release (top) and lysosomal disruption (bottom). U2OS cells were loaded with Fluo-4 AM and LysoTracker® Red (LTR). Baseline fluorescence values were recorded for 15 min before addition of test compounds (30μM). Fluorescence was then monitored for 40 min before addition of GPN (300μM) to release lysosomal Ca2+. Measurements were made to quantify GPN evoked Ca2+ release (top) and loss of LTR fluorescence following initial drug addition (bottom) by assessing fluorescence ratio values in the regions highlighted by the green (peak F/Fo ratio) and red bars (minimal F/Fo ratio). PIC, protease inhibitor cocktail; BafA1, bafilomycin A1. B, Correlation plot depicting relationship between measurements of GPN induced calcium release (y-axis, green) and drug-induced lysosome disruption (x-axis red). Values are replotted from highlighted regions in (A). The cluster of non-lysomotropic compounds is highlighted (box). Data represents peak fluo-4 fluorescence ratios (Ffluo/F0, where ‘Ffluo’ represents fluo-4 fluorescence at peak, and F0 represents fluorescence at time = 0) and minimum LysoTracker® fluorescence ratios (FLTR/F0, where ‘FLTR’ represents minimum LysoTracker® Red fluorescence prior to GPN addition, and F0 represents fluorescence at time = 0). Compounds are labeled according to ranking # in Table 1.
	Fig. 6. Validation of NAADP-inhibitors in mammalian cells. A, Ca2+ traces resolved by fluo-4 fluorescence in response to NAADP microinjection (100 nM pipette concentration) in U2OS cells treated with indicated drugs (10μM, 10 min pretreatment). Individual traces shown in red, averaged response shown in black. B, Quantification of peak amplitude of NAADP-evoked Ca2+ transients in microinjected U2OS cells relative to control (blue bars) following preincubation with indicated drugs as shown in (A). Red bars report luciferase levels in a MERS-pseudovirus cell translocation assay in Huh7 cells relative to controls (H2O, DMSO) following treatment with the same panel of drugs (10μM for 1 h prior to exposure to MERS-pseudovirus for a 5 h period). MERS-pseudovirus cell entry was detected 3 days post infection by measuring luciferase activity as described fully in the companion paper [25]. p-values: * p < 0.05, ** p < 0.01 relative to DMSO controls.

Aarhus, Activation and inactivation of Ca2+ release by NAADP+. 1996, Pubmed, Echinobase

Aarhus, Activation and inactivation of Ca2+ release by NAADP+. 1996, Pubmed , Echinobase
Ali, Activity of nicotinic acid substituted nicotinic acid adenine dinucleotide phosphate (NAADP) analogs in a human cell line: difference in specificity between human and sea urchin NAADP receptors. 2014, Pubmed , Echinobase
Ali, Nicotinic Acid Adenine Dinucleotide Phosphate Plays a Critical Role in Naive and Effector Murine T Cells but Not Natural Regulatory T Cells. 2016, Pubmed
Belinson, Activation of the amyloid cascade in apolipoprotein E4 transgenic mice induces lysosomal activation and neurodegeneration resulting in marked cognitive deficits. 2008, Pubmed
Berg, Use of glycyl-L-phenylalanine 2-naphthylamide, a lysosome-disrupting cathepsin C substrate, to distinguish between lysosomes and prelysosomal endocytic vacuoles. 1994, Pubmed
Billington, Triazine dyes are agonists of the NAADP receptor. 2004, Pubmed , Echinobase
Billington, PPADS is a reversible competitive antagonist of the NAADP receptor. 2007, Pubmed , Echinobase
Brailoiu, Essential requirement for two-pore channel 1 in NAADP-mediated calcium signaling. 2009, Pubmed
Brailoiu, An NAADP-gated two-pore channel targeted to the plasma membrane uncouples triggering from amplifying Ca2+ signals. 2010, Pubmed
Brailoiu, An ancestral deuterostome family of two-pore channels mediates nicotinic acid adenine dinucleotide phosphate-dependent calcium release from acidic organelles. 2010, Pubmed , Echinobase
Calcraft, NAADP mobilizes calcium from acidic organelles through two-pore channels. 2009, Pubmed
Cang, mTOR regulates lysosomal ATP-sensitive two-pore Na(+) channels to adapt to metabolic state. 2013, Pubmed
Capel, Two-pore Channels (TPC2s) and Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) at Lysosomal-Sarcoplasmic Reticular Junctions Contribute to Acute and Chronic β-Adrenoceptor Signaling in the Heart. 2015, Pubmed
Chung, Acid Sphingomyelinase Inhibition Prevents Development of Sepsis Sequelae in the Murine Liver. 2017, Pubmed
Clapper, Pyridine nucleotide metabolites stimulate calcium release from sea urchin egg microsomes desensitized to inositol trisphosphate. 1987, Pubmed , Echinobase
Dickey, Thio-NADP is not an antagonist of NAADP. 1998, Pubmed , Echinobase
Dowden, Cell-permeant small-molecule modulators of NAADP-mediated Ca2+ release. 2006, Pubmed , Echinobase
Dyall, Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. 2014, Pubmed
Favia, VEGF-induced neoangiogenesis is mediated by NAADP and two-pore channel-2-dependent Ca2+ signaling. 2014, Pubmed
Galione, A primer of NAADP-mediated Ca(2+) signalling: From sea urchin eggs to mammalian cells. 2015, Pubmed , Echinobase
Galione, Preparation and use of sea urchin egg homogenates for studying NAADP-mediated Ca²⁺ release. 2014, Pubmed , Echinobase
Genazzani, Pharmacological properties of the Ca2+-release mechanism sensitive to NAADP in the sea urchin egg. 1997, Pubmed , Echinobase
Grimm, From mucolipidosis type IV to Ebola: TRPML and two-pore channels at the crossroads of endo-lysosomal trafficking and disease. 2017, Pubmed
Grimm, Two-Pore Channels: Catalyzers of Endolysosomal Transport and Function. 2017, Pubmed
Grimm, High susceptibility to fatty liver disease in two-pore channel 2-deficient mice. 2014, Pubmed
Gulbins, Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs. 2013, Pubmed
Gunaratne, A screening campaign in sea urchin egg homogenate as a platform for discovering modulators of NAADP-dependent Ca2+ signaling in human cells. 2018, Pubmed , Echinobase
Gunaratne, NAADP-dependent Ca2+ signaling regulates Middle East respiratory syndrome-coronavirus pseudovirus translocation through the endolysosomal system. 2018, Pubmed
Guo, Structure of the voltage-gated two-pore channel TPC1 from Arabidopsis thaliana. 2016, Pubmed
Hockey, Dysregulation of lysosomal morphology by pathogenic LRRK2 is corrected by TPC2 inhibition. 2015, Pubmed
Höglinger, Intracellular sphingosine releases calcium from lysosomes. 2015, Pubmed
Jain, Nicotinic acid adenine dinucleotide phosphate analogues containing substituted nicotinic acid: effect of modification on Ca(2+) release. 2010, Pubmed , Echinobase
Jha, Convergent regulation of the lysosomal two-pore channel-2 by Mg²⁺, NAADP, PI(3,5)P₂ and multiple protein kinases. 2014, Pubmed
Kelu, Ca2+ release via two-pore channel type 2 (TPC2) is required for slow muscle cell myofibrillogenesis and myotomal patterning in intact zebrafish embryos. 2017, Pubmed
Kintzer, Structure, inhibition and regulation of two-pore channel TPC1 from Arabidopsis thaliana. 2016, Pubmed
Kornhuber, Identification of novel functional inhibitors of acid sphingomyelinase. 2011, Pubmed
Kornhuber, Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. 2010, Pubmed
Lear, Absence of intracellular ion channels TPC1 and TPC2 leads to mature-onset obesity in male mice, due to impaired lipid availability for thermogenesis in brown adipose tissue. 2015, Pubmed
Lee, A derivative of NADP mobilizes calcium stores insensitive to inositol trisphosphate and cyclic ADP-ribose. 1995, Pubmed , Echinobase
Lee, Calcium mobilization by dual receptors during fertilization of sea urchin eggs. 1993, Pubmed , Echinobase
Lee, Nicotinic acid adenine dinucleotide phosphate (NAADP)-mediated calcium signaling. 2005, Pubmed , Echinobase
Lemieux, Quantitation of the lysosomotropic character of cationic amphiphilic drugs using the fluorescent basic amine Red DND-99. 2004, Pubmed
Lin, Lysosomal two-pore channel subtype 2 (TPC2) regulates skeletal muscle autophagic signaling. 2015, Pubmed
Lin-Moshier, Photoaffinity labeling of nicotinic acid adenine dinucleotide phosphate (NAADP) targets in mammalian cells. 2012, Pubmed , Echinobase
Lloyd-Evans, Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. 2008, Pubmed
Marchant, The Molecular Basis for Ca2+ Signalling by NAADP: Two-Pore Channels in a Complex? 2012, Pubmed
Merritt, SK&F 96365, a novel inhibitor of receptor-mediated calcium entry. 1990, Pubmed
Morgan, Carvedilol inhibits cADPR- and IP3-induced Ca2+ release. 2016, Pubmed , Echinobase
Morgan, TPC: the NAADP discovery channel? 2015, Pubmed
Morgan, Molecular mechanisms of endolysosomal Ca2+ signalling in health and disease. 2011, Pubmed
Nadanaciva, A high content screening assay for identifying lysosomotropic compounds. 2011, Pubmed
Naylor, Identification of a chemical probe for NAADP by virtual screening. 2009, Pubmed , Echinobase
Padamsey, Activity-Dependent Exocytosis of Lysosomes Regulates the Structural Plasticity of Dendritic Spines. 2017, Pubmed
Pafumi, Naringenin Impairs Two-Pore Channel 2 Activity And Inhibits VEGF-Induced Angiogenesis. 2017, Pubmed
Patel, Function and dysfunction of two-pore channels. 2015, Pubmed
Rahman, Two-pore channels provide insight into the evolution of voltage-gated Ca2+ and Na+ channels. 2014, Pubmed , Echinobase
Rosen, Analogues of the nicotinic acid adenine dinucleotide phosphate (NAADP) antagonist Ned-19 indicate two binding sites on the NAADP receptor. 2009, Pubmed , Echinobase
Ruas, Expression of Ca²⁺-permeable two-pore channels rescues NAADP signalling in TPC-deficient cells. 2015, Pubmed
Sakurai, Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment. 2015, Pubmed
Schnute, Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. 2012, Pubmed
She, Structural insights into the voltage and phospholipid activation of the mammalian TPC1 channel. 2018, Pubmed
Singh, The transient receptor potential channel antagonist SKF96365 is a potent blocker of low-voltage-activated T-type calcium channels. 2010, Pubmed
Strange, Drug Discovery in Fish, Flies, and Worms. 2016, Pubmed
Suárez-Cortés, Ned-19 inhibition of parasite growth and multiplication suggests a role for NAADP mediated signalling in the asexual development of Plasmodium falciparum. 2017, Pubmed
Vasudevan, Scaffold hopping with virtual screening from IP3 to a drug-like partial agonist of the inositol trisphosphate receptor. 2014, Pubmed
Villamil Giraldo, Lysosomotropic agents: impact on lysosomal membrane permeabilization and cell death. 2014, Pubmed
Walseth, Nicotinic Acid Adenine Dinucleotide 2'-Phosphate (NAADP) Binding Proteins in T-Lymphocytes. 2012, Pubmed
Walseth, Synthesis and characterization of antagonists of cyclic-ADP-ribose-induced Ca2+ release. 1993, Pubmed , Echinobase
Walseth, Photoaffinity labeling of high affinity nicotinic acid adenine dinucleotide phosphate (NAADP)-binding proteins in sea urchin egg. 2012, Pubmed , Echinobase
Wang, TPC proteins are phosphoinositide- activated sodium-selective ion channels in endosomes and lysosomes. 2012, Pubmed
Zhang, A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. 1999, Pubmed
Zong, The two-pore channel TPCN2 mediates NAADP-dependent Ca(2+)-release from lysosomal stores. 2009, Pubmed
de Duve, Commentary. Lysosomotropic agents. 1974, Pubmed